We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+18.27%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$715M
AUM Growth
+$146M
Cap. Flow
+$89.1M
Cap. Flow %
12.46%
Top 10 Hldgs %
60.6%
Holding
38
New
7
Increased
10
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
DNTH icon
Dianthus Therapeutics
DNTH
+$28.7M
2
BPMC
Blueprint Medicines
BPMC
+$22.8M
3
FMI
Foundation Medicine, Inc.
FMI
+$15M
4
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$10.7M
5
BLUE
bluebird bio
BLUE
+$9.68M

Top Sells

Rank Stock Value
1
EVH icon
Evolent Health
EVH
+$10.6M
2
IBB icon
iShares Biotechnology ETF
IBB
+$10.1M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$5.46M
4
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$3.75M
5
GNMK
GenMark Diagnostics, Inc
GNMK
+$2.97M

Sector Composition

Rank Sector Weight
1 Healthcare 90.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NEOG icon
26
Neogen
NEOG
$2.59B
$5.21M 0.73%
130,000
– –
CTMX icon
27
CytomX Therapeutics
CTMX
$690M
$4.74M 0.66%
207,500
– –
NTGN
28
DELISTED
Neon Therapeutics, Inc. Common Stock
NTGN
$4.26M 0.6%
+338,345
New +$4.63M
LOXO
29
PUT
DELISTED
Loxo Oncology, Inc
LOXO
$3.47M 0.49%
+20,000
New +$3.01M
ZLAB icon
30
Zai Lab
ZLAB
$2.05B
$3.14M 0.44%
135,000
– –
JNCE
31
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$2.87M 0.4%
375,000
-260,000
-41% -$3.75M
CDNA icon
32
CareDx
CDNA
$2.48B
$2.45M 0.34%
+200,000
New +$2.29M
QTTB icon
33
Q32 Bio
QTTB
$450M
$2.35M 0.33%
6,389
+3,056
+92% +$1.09M
GBT
34
PUT
DELISTED
Global Blood Therapeutics, Inc.
GBT
$2.26M 0.32%
+50,000
New +$2.28M
BPMC
35
CALL
DELISTED
Blueprint Medicines
BPMC
$635K 0.09%
+10,000
New +$796K
ADVM
36
DELISTED
Adverum Biotechnologies
ADVM
– –
-30,000
Closed -$1.74M
IBB icon
37
iShares Biotechnology ETF
IBB
$9.21B
– –
-95,000
Closed -$10.1M
CELG
38
CALL
DELISTED
Celgene Corp
CELG
– –
-40,000
Closed -$3.57M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q2 2018 Portfolio in Review

As of Q2 2018, Casdin Capital held 38 positions worth $715M, up 26% from $569M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Casdin Capital deployed $89.1M of net new capital in Q2 2018, opening 7 new positions and adding to 10 existing holdings. Its largest new stake was Dianthus Therapeutics: 127,239 shares worth $27.5M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 88% a quarter earlier.

On the sell side, the largest reduction was Evolent Health, an estimated $10.6M trimmed.

  • Casdin Capital's largest Q2 2018 buy was Dianthus Therapeutics: 127,239 shares worth $27.5M.
  • Casdin Capital added most to Blueprint Medicines in Q2 2018, an estimated $22.8M increase.
  • Casdin Capital's biggest Q2 2018 reduction was Evolent Health, cutting an estimated $10.6M.
  • Casdin Capital fully exited iShares Biotechnology ETF in Q2 2018, selling an estimated $10.1M.
  • Casdin Capital's ten largest holdings make up 61% of its $715M portfolio in Q2 2018.
  • Casdin Capital opened 7 new positions and closed 3 in Q2 2018.
  • Casdin Capital's portfolio value rose 26% quarter-over-quarter to $715M.

Based on Casdin Capital's 13F filing for Q2 2018, filed 14 Aug 2018.